2018 Q4 Form 10-K Financial Statement

#000143774920006370 Filed on March 30, 2020

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $17.56M $67.14M $18.89M
YoY Change -7.02% -5.54% 12.11%
Cost Of Revenue $7.590M $27.57M $6.460M
YoY Change 17.49% 50.1% 17.67%
Gross Profit $9.973M $39.57M $12.44M
YoY Change -19.83% -8.74% 9.51%
Gross Profit Margin 56.78% 58.94% 65.85%
Selling, General & Admin $8.610M $34.51M $10.17M
YoY Change -15.34% -1.43% 3.25%
% of Gross Profit 86.33% 87.2% 81.75%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.237M $6.659M $1.480M
YoY Change -16.42% -4.37% -86.23%
% of Gross Profit 12.4% 16.83% 11.9%
Operating Expenses $9.847M $39.16M $11.64M
YoY Change -15.4% -17.0% 4.77%
Operating Profit $126.0K $415.0K $800.0K
YoY Change -84.25% -110.89% 220.0%
Interest Expense -$439.0K $1.420M -$320.0K
YoY Change 37.19% 6.61% -3.03%
% of Operating Profit -348.41% 342.17% -40.0%
Other Income/Expense, Net -$18.00K -$1.457M $0.00
YoY Change 0.83% -100.0%
Pretax Income -$331.0K -$1.042M -$1.630M
YoY Change -79.69% -80.18% 103.75%
Income Tax -$56.00K $53.00K -$640.0K
% Of Pretax Income
Net Earnings -$275.0K -$1.095M -$17.99M
YoY Change -98.47% -94.71% 3727.66%
Net Earnings / Revenue -1.57% -1.63% -95.24%
Basic Earnings Per Share -$0.05
Diluted Earnings Per Share -$14.07K -$0.05 -$789.7K
COMMON SHARES
Basic Shares Outstanding 21.42M 22.78M shares
Diluted Shares Outstanding 21.42M

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.318M $4.318M $3.500M
YoY Change 23.37% 24.47% 2.94%
Cash & Equivalents $4.318M $4.318M $3.469M
Short-Term Investments
Other Short-Term Assets $1.372M $1.372M $1.150M
YoY Change 19.3% 19.3% 21.18%
Inventory $2.254M $2.254M $1.764M
Prepaid Expenses
Receivables $9.593M $9.593M $11.28M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.54M $17.54M $17.67M
YoY Change -0.74% -0.74% -14.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.445M $26.53M $1.633M
YoY Change -11.51% -0.13% -18.23%
Goodwill
YoY Change
Intangibles $19.87M $24.51M
YoY Change -18.96% -21.53%
Long-Term Investments
YoY Change
Other Assets $137.0K $137.0K $131.0K
YoY Change 4.58% 4.58% -41.78%
Total Long-Term Assets $46.54M $46.54M $51.21M
YoY Change -9.13% -9.13% -32.23%
TOTAL ASSETS
Total Short-Term Assets $17.54M $17.54M $17.67M
Total Long-Term Assets $46.54M $46.54M $51.21M
Total Assets $64.07M $64.07M $68.88M
YoY Change -6.98% -6.98% -28.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.091M $7.091M $5.516M
YoY Change 28.55% 28.55% 3.78%
Accrued Expenses $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.903M $4.936M $3.039M
YoY Change 61.34% 39.28% -42.81%
Total Short-Term Liabilities $14.79M $14.79M $12.47M
YoY Change 18.57% 18.57% -24.12%
LONG-TERM LIABILITIES
Long-Term Debt $28.84M $28.84M $25.35M
YoY Change 13.77% 13.62% -4.61%
Other Long-Term Liabilities $0.00 $7.000K
YoY Change -100.0% -89.39%
Total Long-Term Liabilities $43.63M $28.84M $37.93M
YoY Change 15.04% 13.59% 29.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.79M $14.79M $12.47M
Total Long-Term Liabilities $43.63M $28.84M $37.93M
Total Liabilities $43.63M $43.63M $37.93M
YoY Change 15.04% 15.04% -16.92%
SHAREHOLDERS EQUITY
Retained Earnings -$62.73M -$61.63M
YoY Change 1.78% 49.81%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.44M $20.44M $30.95M
YoY Change
Total Liabilities & Shareholders Equity $64.07M $64.07M $68.88M
YoY Change -6.98% -6.98% -28.51%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$275.0K -$1.095M -$17.99M
YoY Change -98.47% -94.71% 3727.66%
Depreciation, Depletion And Amortization $1.237M $6.659M $1.480M
YoY Change -16.42% -4.37% -86.23%
Cash From Operating Activities $3.181M $11.39M $3.620M
YoY Change -12.13% 47.59% -13.19%
INVESTING ACTIVITIES
Capital Expenditures -$3.782M $281.0K -$120.0K
YoY Change 3051.67% 170.19% -93.33%
Acquisitions
YoY Change
Other Investing Activities $975.0K $3.319M $350.0K
YoY Change 178.57% -14.15% -69.3%
Cash From Investing Activities -$2.807M -$4.984M $230.0K
YoY Change -1320.43% -642.92% -135.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.40M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 62.00K -5.558M -1.180M
YoY Change -105.25% -35.11% -0.84%
NET CHANGE
Cash From Operating Activities 3.181M 11.39M 3.620M
Cash From Investing Activities -2.807M -4.984M 230.0K
Cash From Financing Activities 62.00K -5.558M -1.180M
Net Change In Cash 436.0K 849.0K 2.670M
YoY Change -83.67% 1095.77% 14.59%
FREE CASH FLOW
Cash From Operating Activities $3.181M $11.39M $3.620M
Capital Expenditures -$3.782M $281.0K -$120.0K
Free Cash Flow $6.963M $11.11M $3.740M
YoY Change 86.18% 45.92% -37.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001337013
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19960880
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
52431233
CY2019 dei Entity Registrant Name
EntityRegistrantName
InfuSystem Holdings, Inc
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2019 dei Trading Symbol
TradingSymbol
infu
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Current
CapitalAndOperatingLeasesFutureMinimumPaymentsCurrent
1778000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due
CapitalAndOperatingLeasesFutureMinimumPaymentsDue
8182000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Five Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInFiveYears
636000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Four Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInFourYears
624000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Three Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInThreeYears
726000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due In Two Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInTwoYears
1347000
CY2018Q4 infu Capital And Operating Leases Future Minimum Payments Due Thereafter
CapitalAndOperatingLeasesFutureMinimumPaymentsDueThereafter
3071000
CY2019 infu Concentration Risk Percentage Of Raw Material Purchases From Suppliers Minimum Threshold
ConcentrationRiskPercentageOfRawMaterialPurchasesFromSuppliersMinimumThreshold
0.1
CY2019 infu Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
CY2018 infu Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
CY2019 infu Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
120000
CY2018 infu Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
65000
CY2019 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
7500000
CY2018 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
6200000
CY2019 infu Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.058
CY2018 infu Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.094
CY2014Q2 infu Employee Stock Ownership Plan Esop Purchase Per Employee Maximum
EmployeeStockOwnershipPlanESOPPurchasePerEmployeeMaximum
25000
CY2014Q2 infu Employee Stock Purchase Plan Discount Rate
EmployeeStockPurchasePlanDiscountRate
0.15
CY2019 infu Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
3.94
CY2018 infu Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
2.45
CY2019Q4 infu Longterm Debt Maturities Repayments Of Principal In Year Five And Thereafter
LongtermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter
9809000
CY2019Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1306000
CY2018Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1601000
CY2019Q4 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
1334000
CY2018Q4 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
1601000
CY2018Q4 infu Medical Equipment Held For Sale Or Rental Reserve
MedicalEquipmentHeldForSaleOrRentalReserve
0
CY2019Q4 infu Medical Equipment Held For Sale Or Rental Reserve
MedicalEquipmentHeldForSaleOrRentalReserve
28000
CY2019Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
33225000
CY2018Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
23488000
CY2019Q4 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
41908000
CY2018Q4 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
37411000
CY2019Q4 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
75853000
CY2018Q4 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
61429000
CY2019Q4 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
720000
CY2018Q4 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
530000
CY2019 infu Medical Equipment In Rental Services Useful Life
MedicalEquipmentInRentalServicesUsefulLife
P7Y
CY2019Q4 infu Medical Equipment Net
MedicalEquipmentNet
34531000
CY2018Q4 infu Medical Equipment Net
MedicalEquipmentNet
25089000
CY2019 infu Net Operating Loss Carryforwards Limitation On Use
NetOperatingLossCarryforwardsLimitationOnUse
1800000
CY2019Q4 infu Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2019 infu Number Of Leases Entered Into During The Period For Additional Office And Warehouse Space
NumberOfLeasesEnteredIntoDuringThePeriodForAdditionalOfficeAndWarehouseSpace
4
CY2019 infu Number Of Leases Entered Into During The Period For Equipment
NumberOfLeasesEnteredIntoDuringThePeriodForEquipment
4
CY2019Q4 infu Number Of Operating Locations
NumberOfOperatingLocations
5
CY2019 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
19669000
CY2018 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
8022000
CY2019 infu Reductions To Right Of Use Assets Resulting From Reductions To Lease Obligations
ReductionsToRightOfUseAssetsResultingFromReductionsToLeaseObligations
22000
CY2019Q4 infu Remaining Preownership Net Operating Loss Carryforwards
RemainingPreownershipNetOperatingLossCarryforwards
4700000
CY2019 infu Revenues External
RevenuesExternal
81115000
CY2018 infu Revenues External
RevenuesExternal
67138000
CY2019 infu Revenues Internal
RevenuesInternal
CY2018 infu Revenues Internal
RevenuesInternal
CY2019Q4 infu Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance
217688
CY2018Q3 infu Stock Repurchase Agreement Shares To Be Repurchased
StockRepurchaseAgreementSharesToBeRepurchased
2800000
CY2019Q4 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
17000
CY2018Q4 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
38000
CY2019Q4 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
66000
CY2018Q4 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
76000
CY2019Q4 infu Unamortized Value Of Debt Issuance Costs Principal Current
UnamortizedValueOfDebtIssuanceCostsPrincipalCurrent
17000
CY2019Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Five And Thereafter
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFiveAndThereafter
15000
CY2019Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Four
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFour
17000
CY2019Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Three
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearThree
17000
CY2019Q4 infu Unamortized Value Of Debt Issuance Costs Principal In Year Two
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearTwo
17000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7962000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7091000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12097000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9593000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2648000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4609000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83699000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83167000
CY2018 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
70000
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
717000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
91000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
113000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
957000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
997000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
37000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
33000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4402000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4649000
CY2019Q4 us-gaap Assets
Assets
79224000
CY2018Q4 us-gaap Assets
Assets
64073000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
19305000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
17537000
CY2019 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> </td> <td> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Basis of Presentation and Nature of Operations</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.5pt;">InfuSystem Holdings, Inc. and its consolidated subsidiaries (the &#x201c;Company&#x201d;) are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> locations in the United States and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. InfuSystem Inc., which is an operating subsidiary of the Company, is accredited by the Community Health Accreditation Program while First Biomedical, Inc., which is an operating subsidiary of the Company, is ISO certified.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.5pt;">The Company&#x2019;s core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company&#x2019;s pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supply more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of the ambulatory pumps purchased by the Company. The Company has a supply agreement in place with each of these suppliers. Certain &#x201c;spot&#x201d; purchases are made on the open market subject to individual negotiation.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.5pt;">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for, oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the hospital market.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.5pt;">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company&#x2019;s ambulatory infusion pump management service.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.5pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).</div></div>
CY2019 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1671000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
849000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2773000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
998000
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
33000
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
33000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
33000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
33000
CY2019 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
2000000
CY2018 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
2300000
CY2019Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
0
CY2018Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
0
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4318000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3469000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2647000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23400625
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23095513
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19882136
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19577024
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Customer Concentration</div></div> <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company&#x2019;s largest contracted payor was a national payor which accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7%</div> of our net revenues from its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor oncology business for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively, and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4%</div> of its total net revenues for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.5pt;">The Company also contracts with various other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payor noted above, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> other single payor represented more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6%</div> of the Company&#x2019;s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor net revenue.</div></div></div></div></div></div></div></div>
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
34233000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27568000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
30000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
31000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
29000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
84000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
104000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-62000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
104000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-62000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
104000
CY2018Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9400000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11370000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11435000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11250000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
104000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
CY2019 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
700000
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
600000
CY2019 us-gaap Depreciation
Depreciation
7940000
CY2018 us-gaap Depreciation
Depreciation
6659000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
12342000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
11307000
CY2019 us-gaap Depreciation Nonproduction
DepreciationNonproduction
500000
CY2018 us-gaap Depreciation Nonproduction
DepreciationNonproduction
400000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.107
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.05
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.079
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.02
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.022
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.14
CY2019 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
43030
CY2018 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
33874
CY2014Q2 us-gaap Employee Stock Ownership Plan Esop Shares Contributed To Esop
EmployeeStockOwnershipPlanESOPSharesContributedToESOP
200000
CY2019 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
104000
CY2018 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-62000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
34324000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
29922000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2101000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4285000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
548000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
548000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2051000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3930000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1453000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1340000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29023000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25399000
CY2019 us-gaap Gross Profit
GrossProfit
46882000
CY2018 us-gaap Gross Profit
GrossProfit
39570000
CY2019Q4 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
638000
CY2018 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
434000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
1413000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1138000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1524000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1042000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
111000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
96000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1524000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1042000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
163000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
53000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
111000
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
159000
CY2019 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
2436000
CY2018 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
183000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1560000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1909000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
645000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
490000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
290000
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
222000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
129000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6000
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1107898
CY2018 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
49787000
CY2018Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
49787000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15463000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19865000
CY2019 us-gaap Interest Expense
InterestExpense
1904000
CY2018 us-gaap Interest Expense
InterestExpense
1420000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1705000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1383000
CY2019Q4 us-gaap Inventory Net
InventoryNet
2899000
CY2018Q4 us-gaap Inventory Net
InventoryNet
2254000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2019 us-gaap Lease Cost
LeaseCost
2239000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8526000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3166000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1532000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
947000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
924000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
947000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1010000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2471000
CY2019Q4 us-gaap Liabilities
Liabilities
56890000
CY2018Q4 us-gaap Liabilities
Liabilities
43632000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79224000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64073000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21847000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14790000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
38377000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
33745000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8082000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4903000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
8082000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6513000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6735000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7238000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30295000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28842000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4097000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5558000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19643000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4984000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13875000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11391000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
1361000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-1095000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8149000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5803000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2796000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2019Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2019 us-gaap Operating Expenses
OperatingExpenses
43357000
CY2018 us-gaap Operating Expenses
OperatingExpenses
39155000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
3525000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
415000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1948000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3100000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6055000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4644000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1610000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3100000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5733000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.077
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y146D
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1745000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
636000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
624000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
726000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1347000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
3071000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
38100000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1662000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1372000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-97000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10395000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
6000
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
27000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
717000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
70000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2926000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
281000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Reclassifications</div></div> <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.5pt;">Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> effect on reported income (loss), overall cash flows, total assets, total liabilities or stockholders&#x2019; equity as previously reported.</div></div></div></div></div></div></div></div>
CY2019 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
9436000
CY2018 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
11162000
CY2019 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
2952000
CY2018 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
3319000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
252000
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
91000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6685000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6054000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4037000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1445000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
37000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-218000
CY2019 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
4868000
CY2018 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
6319000
CY2019 us-gaap Restricted Stock Expense
RestrictedStockExpense
190000
CY2018 us-gaap Restricted Stock Expense
RestrictedStockExpense
78000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61367000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62728000
CY2019 us-gaap Revenues
Revenues
81115000
CY2018 us-gaap Revenues
Revenues
67138000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4545000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9932000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9107000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
997000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
957000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.61
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
350000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y229D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y302D
CY2018 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
100000
CY2019 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
100000
CY2019 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
29000
CY2018 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
84000
CY2019 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
33742
CY2018 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
43433
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
139000
CY2019 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
807000
CY2018 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
879000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
30953000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
20441000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
22334000
CY2018 us-gaap Treasury Stock Value Acquired Par Value Method
TreasuryStockValueAcquiredParValueMethod
10395000
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
83000
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
114000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21417628
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19731498
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21417628
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Use</div><div style="display: inline; font-style: italic;"> of Estimates</div></div> <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.5pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div>
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
291000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20839396

Files In Submission

Name View Source Status
0001437749-20-006370-index-headers.html Edgar Link pending
0001437749-20-006370-index.html Edgar Link pending
0001437749-20-006370.txt Edgar Link pending
0001437749-20-006370-xbrl.zip Edgar Link pending
ex_178388.htm Edgar Link pending
ex_178389.htm Edgar Link pending
ex_178390.htm Edgar Link pending
ex_178391.htm Edgar Link pending
ex_178392.htm Edgar Link pending
ex_178393.htm Edgar Link pending
ex_178395.htm Edgar Link pending
ex_178396.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
infu-20191231.xml Edgar Link completed
infu-20191231.xsd Edgar Link pending
infu-20191231_cal.xml Edgar Link unprocessable
infu-20191231_def.xml Edgar Link unprocessable
infu-20191231_lab.xml Edgar Link unprocessable
infu-20191231_pre.xml Edgar Link unprocessable
infu20191231_10k.htm Edgar Link pending
infu20191231_10kimg001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending